Orforglipron (TBC) to Reduce Excess Body Weight and Maintain Weight Reduction Long Term in Adults
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for orforglipron (TBC) as an adjunct to healthy diet and physical activity: to reduce excess body weight and maintain weight reduction long term in adults with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).